News
Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback